Neotherix is delighted to receive further funding from the Technology Strategy Board to continue the development of our lead product EktoTherix regenerative tissue scaffold for the repair of surgical excisions and other acute wounds. The funding will take EktoTherix through to first-in-man clinical studies, which are expected to be initiated one year from the start of the project.
Fourteen regenerative medicine projects have been awarded a total of £8.5 million grant funding by the Technology Strategy Board. For more details please see the Technology Strategy Board press release . |